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PREFACE 
This study characterizes monensin toxicosis in the horse. Clinical 
signs and physiological parameters were closely monitored in four horses 
given various dosages of monensin. 
changes occurred in the myocardium. 
The most obvious degenerative 
The changes noted on necropsy 
examination, histopathologic and electron microscopic examinations are 
described. These descriptions will be helpful in diagnosing and in 
developing treatment regiments for monensin poisoning in horses. The 
toxicity of monensin to horses based on this study is compared to 
previously reported values. 
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CHAPTER I 
THE RESEARCH PROBLEM 
Monensin is a metabolite of the fungus Streptomyces cinnamonesis. 
The fungus was first cultured in 1964 from an Arizona soil sample (1). 
Shumard and Callender (2) reported on the anticoccidial activity of 
monensin in 1967. Monensin was made commercially available as a poultry 
coccidiostat in 1971 and is sold under the trade names of Caban R 1 and 
R 2 Elancoban. In recent years monensin has had about 80% of the poultry 
coccidiostat market in the United States. 
The effect of monensin on ruminal fermentation was reported in 1974 
(3) (4). Monensin as a feed additive was shown to increase feed 
efficiency in cattle 10 to 15%. Subsequently monensin was introduced as 
a feed additive for cattle under the trade name of Rumensin. R 3 An 
estimated 60 million cattle are fed monensin annually. 
A warning was issued in 1975 to veterinarians and users of 
R Elancoban that the product may be hazardous to horses. The product 
label was changed to include the statement: "DO NOT FEED TO HORSES OR 
OTHER EQUINES - MAY BE FATAL." 
The oral LD50 of monensin for horses is approximately 2 mg/kg (1). 
1 R Cob an - Monensin, Elanco Products Company, Indianapolis, IN. 
2Elanc.obanR - Lilly International, Indianapolis, IN. 
3RumensinR - Monensin, Elanco Products Company, Indianapolis, IN. 
1 
This compares with an oral LD50 for cattle of approximately 22 mg/kg, 
17mg/kg for swine, and 200 mg/kg for chickens (37). The reasons for 
such variation in species susceptibility is not completely understood. 
Concentrations of monensin used in medicated poultry feed, premixes for 
cattle feed, and in cattle feed supplements are great enough to cause 
death in horses when consumption of small to moderate amounts occurs. 
The mechanisms of action of monensin poisoning in horses is not known. 
The extensive use of monensin as a feed additive and coccidiostat makes 
the likelihood of accidental exposure to horses great. This makes 
monensin a hazardous compound for horses. 
An effective treatment for monensin poisoning has not been found 
and few reports describing symptomatology, pathology and diagnosis have 
appeared in the literature. 
; t:1fi~s study was undertaken to investigate monensin poisoning in 
, .. ~~ '. '. . 
horses. The project includes clinical observations, hematologic and 
clinicopathologic analyses of blood and serum, electrocardiographs, 
necropsy, histopathologic and electron microscopic studies of tissues of 
experimental horses given varied dosages of monensin, and control 
horses.' It was believed that such a study would result in a better 
understanding of monensin toxicosis in horses. 
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CHAPTER II 
REVIEW OF THE LITERATURE 
Monensin is an antibiotic that inhibits gram positive bacteria and 
is effective in controling coccidia in chickens. It belongs to the 
class of antibiotics called polyether carboxylic ionophores. 
Ionophores In General 
Ionophores have been defined as compounds possessing the ability to 
form lipid-soluble complexes that provide a vehicle for cations to 
traverse lipid barriers such as biological membranes (5). Harned et. 
al. (6) characterized the first ionophore (Nigericin) in 1951. The 
unique ion-transporting properties of the ionophores were discovered 
seredipitously by Moore and Pressman (7) (8) (9) (10) in 1964. They 
investigated the inhibition of mitochondria by guanidine derivatives and 
found that the oxidative phosphorylation uncoupling action of valino-
mycin (an ionophore derived from a Streptomyces fungus) was different 
from that of classical uncouplers such as dinitrophenol. Valinomycin 
produced a much greater acidification of the mitochondria containing 
medium than could be explained by the hydrolysis of adenosine triphos-
phate (ATP). When a potassium selective electrode was inserted into the 
medium, loss of K+ was approximately equivalent to the quantity of 
hydrogen ions that appeared. Valinomycin apparently catalyzed an energy 
linked K+ for H+ exchange. With increased K+ concentration within the 
3 
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mitochondria there was a corresponding increase in mitochondrial volume 
and rate of respiration (11). 
Ionophores have been used extensively to study ionic transport of 
biological membranes (11) (7) (5) (12) (13) (14) (15). The rate of 
complexation, membrane-transport, decomplexation exceeds that of most 
macromolecular enzymes and is in the range of hundreds-to-thousands per 
second (12). With a specific ionophore, ion specificity ratios observed 
in membrane transport studies depends upon the choice of membrane. In 
studies of the K+ transport rate· across mitochondrial versus erythro-
cytic membranes, valinomycin was a highly specific transporter of K+ 
across both membranes. However, the erythrocytic turnover rate was two 
orders of magnitude lower than the value obtained when rat hepatocytic 
mitochondria were used (12). Differences observed were believed to be 
due to decreased mobility of the complex in erythrocytic membranes due 
to their high cholesterol content or some absorption (and thus inacti-
vation) of the ionophore to hemoglobin or membrane proteins (12). 
Naturally occurring ionophores have recently been isolated from 
mitocondria of bovine myocardium (5). Ionophores may be the universal 
charge-separating species used by all energy-coupling systems (5). 
Ionophores are of moderate molecular weight (200-2000). They form 
complexes which are highly specific for certain cations (K+, Na+, Ca++, 
Mg++) and amines (norepinephrine, serotonin, dopamine, epinephrine). 
Ionophoric molecules in general consist of a backbone of diverse 
structures that contain strategically spaced oxygen atoms (7). The 
structure is capable of assuming a shape in solution that orients oxygen 
atoms centrally to form a hydrophilic cavity capable of complexing with 
cations whose diameter and charge are compatable with that of the 
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cavity. Various hydrocarbon groupings are located on the exterior of 
the molecule. The solubility characteristics of ionophores are due to 
the lipid solubility of peripheral hydrocarbon groups and, because such 
groups shield the polar interior of the molecule, delocalization of the 
cation charge occurs (7). In the case of carboxylic ionophores, 
neutrality of the complex is partially due to the cancellation of the 
central cationic charges by the negative charge of the carboxyl group 
(16). 
Ionophores are presently being used to study the mechanisms of 
oxidative phosphorylation (7) (17). Investigation of the erythrocytic 
transport of ions across membranes utilizing ionophores has established 
that the transport of Cl- and presumably other anions as well, is 
mediated through exchange-diffusion carriers and not through channels as 
was previously believed (11). 
Effects of Ionophores on Cardiac 
and Skeletal Muscle 
Ionophores specific for various cations and amines have been shown 
to have profound effects on cardiac and skeletal muscle (18) (19) (20) 
(21) (22). A calcium ionophore known as X-537A caused rapid release of 
accumulated calcium from vesicles of the sarcoplasmic reticulum and had 
marked contractile effects when applied to isolated preparations of 
skeletal, cardiac and vascular smooth muscle at uM concentrations (18). 
An ionophore known as A204, which was obtained from the 
fermentation of the fungus Streptomyces albus, has a primary myotoxic 
effect on skeletal and cardiac muscles (19). Clinical signs of 
neuromuscular toxicosis in dogs prompted Todd et al. to administer A204 
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to rats. The substance was given by gavage at doses of 2, 4, and 8 
mg/kg. Significant histopathologic lesions were found in skeletal and 
cardiac muscle. The most extensively damaged muscles were those with 
the highest level of activity, such as, the diaphragmatic, abdominal and 
cardiac muscles. Twenty-four hours after a single toxic dose, affected 
muscle fibers were swollen and had an increased eosinophilia and 
homogenous-staining cytoplasm. Later, affected fibers were more 
numerous. Fragmentation, vacuolation and loss of cross striations was 
evident. By 48 hours post-treatment, a cellular infiltrate that con-
sisted mostly of macrophages was evident. Cardiac damage produced by 
A204 were similar to those described in potassium-depleted rats (19). 
Further study of A204 led to the conclusion that A204 blocks re-entry of 
cellular K+ (22). 
A calcium ionophore known as Ro 2-2985 (X537 A) had the following 
effects on the cardiovascular system (21): When administered intra-
venously at a rate of 1 mg/kg to Beagles, Ro 2-2985 produced a· sig-
nificant increase in cardiac output. Total body venous compliance was 
decreased and there was a significant increase in heart rate and mean 
arterial pressure. A significant decrease in total peripheral 
resistance was also observed. Ro 2-2985 altered aortic distensibility 
allowing the accommodation and delivery of larger volumes of blood 
without altering arterial pressures. Thus it increases myocardial 
efficiency with only a slight increase in oxygen consumption. 
In 1972 it was observed that divalent cationic polyether ionophores 
were potent inotropic agents (5). This inotropic effect was ascribed to 
the release of myocardial Ca++ ions.· A single dose (2 mg/Kg i.v. in 
anesthetized dogs) of lasalocid (a calcium ionophore) caused a two-fold 
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increase in contractility, doubled the cardiac output, slightly 
increased blood pressure and heart rate, decreased peripheral resistance 
and decreased coronary resistance. Lasalocid was found to transport 
such amines as serotonin, dopamine, norepinephrine and epinephrine as 
well as Ca++. Thus, it possibly affected the cardiovascular system by 
altering membrane permeability to amines and/or Ca++. 
The relative inotropic activity of six monovalent cation ionophores 
in decreasing order of potency is: A-204A, X-206, monensin, dianemycin, 
nigericin, lasalocid (5). The mechanism of this inotropic effect is not 
fully understood, but it cannot be explain~d entirely on the basis of 
Ca++ and catacholamine transport because monensin and X-206 do not 
transport either species across membranes in vitro. 
Other Uses of Ionophores 
Ionophores have been used in chemistry to dissolve highly reactive 
inorganic compounds in solvents of low polarity (7). Such use can 
tremendously accelerate saponification, oxidation and reduction 
reactions of certain organic compounds. 
Ionophore-doped membranes form the basis of many ion-selective 
electrodes (7). The best glass-based K+ selective membranes available 
show a 20: 1 preference for K+ over Na+. Valinomycin-based electrodes 
exhibit 4000:1 K:Na selectivity preference. 
Calcium ionophores have been used to study the calcium dependent 
release of histamine from isolated mast cells (7). Calcium induced 
exocytosis appeared to be a general mechanism for release of cellular 
secretory products by promoting fusion of secretory granules with plasma 
membranes. 
Properties of Monensin 
Possible Effects of Monensin on Mitochondria 
and ATP Production 
8 
Adenosine triphosphate (ATP) serves as an "energy currency" which 
can be used to power the various functions of cells. In eukaryotic 
cells, oxidative phosphorylation of adenosine diphosphate (ADP) to form 
ATP takes place only in the mitochondrial membrane. The reaction of 
carbohydrates with oxygen to yield energy, carbon dioxide, and water in 
biological systems is called respiration. In mitochondria, hydrogen is 
extracted from carbohydrates and is delivered to nicotinamide adenine 
dinucleotide (NAD+) in the citric acid cycle. 
Nicotinamide adenine dinucleotide hydride (NADH) the reduced form 
of NAD+ is the intermediary between the citric acid cycle and the 
enzymes within the inner mitochondrial membrane. These enzymes, known 
as the respiratory chain eventually deliver electrons to oxygen, forming 
water and ATP. How the transfer of electrons through the respiratory 
chain is coupled to oxidative phosphorylation is not fully understood. 
The chemiosmotic theory was proposed by Peter Mitchell (17) in 1961. He 
suggested that the flow of electrons through the respiratory chain 
resulted in an electrochemical proton gradient across mitochondrial 
membranes. The proposed gradient consisted of a difference of hydrogen 
ion concentration (pH) and a difference in electric potential. The 
phosphorylation of ADP was driven by a reverse flow of protons down the 
gradient. The outer mitochondrial membrane is permeable to hydrogen 
ions allowing passive diffusion of H+ to the cytoplasm. 
Mitochondria require K+ for phosphorylation of ADP to ATP to occur 
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( 15). The uptake of potassium is an energy dependent reaction. The 
calculated total free energy of K+ transport approximates the maximum 
free energy available to mitochondria through hydrolysis of ATP (7). 
The immediate source of energy for K+ transport is not ATP because K+ 
transport is not blocked by inhibition of ATPase. This suggests that 
the two processes are closely coupled. Monensin transports· Na+ and K+ 
ions with an in vitro affinity for Na+ over K+ of 10: 1. Monensin' s 
transport of ions across erythrocytic membranes results in a 
complexation affinity of 5: 1 Na+ :K+ (23). Thus, the degree to which 
monensin favors complexation with Na+ over K+ varies with the type of 
membrane under investigation. 
Monensin in vitro inhibits the uptake of K+ by hepatocytic 
mitochondria of rats (15). The inhibition may be overcome by higher 
potassium concentrations. Inhibition of K+ uptake was attributed to 
inhibition of the energy-linked mitochondrial ion pump by monensin-
alkali-cation complexes. Monensin's inhibition of K+ transport results 
in inhibition of ATP hydrolysis and substrate utilization. 
Monensin also has been shown to catalyze the release of K+ for H+ 
in de-energized mitochondria, erythrocytes, and in microsomes of the 
brain. 
In summary, monensin interferes with the transport of alkaline 
cations across mitochondrial membranes. The exact mechanism of 
monensin's interference of mitochondrial metabolism is not fully 
understood. 
Effects of Monensin on the Cardiovasculature 
Pressman (7) considered monensin to be the most promising of the 
10 
carboxylic ionophores for use in cardiovascular applications. The 
intravenous administration of monensin to anesthetized dogs at the rate 
of 5-25 ug/kg increased coronary blood flow by 3-5 times (maximum 
coronary dilation) and decreased total peripheral resistance (24). The 
response of the coronary blood flow was dose dependent in the 5-100 
ug/kg range. Decreased total peripheral resistance was primarily due to 
the vasodilatory action of monensin. Low doses of monensin (5 and 10 
ug/kg i.v.) reduced aortic blood pressure while 25, 50 & 100 ug/kg i.v. 
caused a marked elevation of aortic blood pressure. Monensin increased 
cardiac output at all doses tested. Heart rate remained essentially 
normal throughout the experiment. Duration of increased cardiac output 
was dose dependent with doses of 5 and 10 ug/kg being transient while 
doses of 25 ug/kg and larger produced increased cardiac output lasting 5 
to 120 minutes. 
Coronary blood flow is regulated by a number of factors including 
oxygen demand resulting from increased heart rate and contractility. 
Coronary dilatation is thought to be mediated by local release of 
vasoactive substances such as adenosine, and/ or prostaglandins. The 
vasodilator action of monensin was not blocked by antagonists of 
histamine, acethylcholine, isoproterenol or inhibitors of prostaglandin 
synthesis (24). Thus, it was believed that the effect of monensin on 
coronary blood flow was due to direct relaxation of blood vessels (24). 
Monensin's positive inotropic effect may be explained by the 
antibiotic's ability to transport Na+ across myocytic membranes. 
Normally low intracellular Na+ concentrations are maintained by a Na+-K+ 
pump located in the myocytic membrane. Increases in intracellular Na+ 
leads to an increase in intracellular Ca+2 • Although the mechanism for 
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contractility of cardiac muscle is not completely understood, it is 
known that increases +2 in intracellular Ca result in increased con-
tractility. The positive inotropic effect of monensin was only 
partially blocked by large doses (5 mg/kg IV) of propranolol, a blocker 
of Beta1 and Beta2 adrenergic receptors (24). This suggested the 
inotropic action of monensin was in part due to a nonadrenergic 
mechanism. 
Tetraodontoxin, a compound that blocks sodium channels in 
membranes, had no effect on the positive inotropic action of monensin. 
Thus, the results obtained from administration of propranolol and 
tetraodontoxin to cardiac muscle under the influence of monensin lends 
further support to the theory that monensin's inotropic effect is the 
. + 
result of increased intracellular Na concentrations. These results 
+ 
were believed to be due to monensin's ability to transport Na across 
myocytic membranes (24). 
The positive inotropic effect of monensin has also been 
demonstrated in guinea-pig and cat myocardia and in rabbit atria (25). 
Other Biological Effects of Monensin 
Monensin was first reported to be moderately active against 
gram-positive organisms and certain mycocobacteria by Haney et al. (26) 
in 1967. Monensin reduces the production of lactic acid and the 
concomitant drop in rumen pH in cattle fed high grain rations (27). 
Monensin is effective in controlling coccidiosis in chickens at a dosage 
of 110 grams per ton of feed (2). 
Hammond, Carlson et al. (28) studied the effect of monensin on the 
conversion of tryptophan to 3-methylindole. In the rumen, 1-tryptophan 
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(a naturally occurring constituent of some forages) is converted to 
indole-acetic acid and then to 3-methylindole. When absorbed into the 
systemic circulation in sufficient quantities 3-methylindole produced 
lesions characteristic of bovine atypical intersitital pneumonia (AIP). 
Monensin, as a feed additive, reduced the formation of 3-methylindole in 
vivo and in vitro. Thus, monensin might be of some value in preventing 
some forms of bovine AIP. 
Monensin, as a feed additive, increased feed efficiency of feedlot 
cattle (4). Monensin alters ruminal microf lora by selecting for 
succinate-forming bacteria that produce proportionally larger amounts of 
proprionate from carbohydrates and correspondingly less acetate, 
butyrate and methane. When carbohydrates are converted to acetate and 
subsequently to butyrate, a pyruvate carbon is converted to methane. 
The energy associated with breaking the C-C bond in pyruvate is wasted • 
• Thus, any compound that shifts the composition of ruminal volatile fatty 
acids to greater amounts of proprionate and lesser amounts of acetate 
and butyrate conserves energy and increases feed efficiency. The energy 
savings associated with a 10 moles/100 moles increase in ruminal 
proprionic acid is approximately 5. 5%. Monensin increased the molar 
proportion of prop ionic acid by approximately this amount. However, 
monensin increases feed efficiency by 10-15% (4). Thus, monensin 
apparently acts in other ways to produce an additional 7-9% increase in 
feed efficiency. It is believed that monensin might increase feed 
efficiency by lowering the heat increment, sparing protein that would 
normally be used in gluconeogenesis, stimulating protein synthesis, 
changing the composition of ingesta reaching the small intestine and 
increasing the extent of digestion (4). 
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Witt et al. (27) found an increased efficiency of 4.8% in Oklahoma 
feedlot cattle receiving monensin supplementation. This increase in 
feed efficiency is more in line with the theoretical increase mentioned 
above. This study involved six feeding trials, 716 cattle, and 16 
different rations. Although increased feed efficiency was not as great 
as that reported by Raun et al. (10-15%), it was concluded that monensin 
supplementation was economically advantageous. 
Monensin Tissue Distribution and Metabolism 
The distribution of monensin in the tissues of several species was 
studied by the use of monensin that had been labeled with tritium or 
carbon-fourteen (29) (3) (30). The route of administration in each study 
was oral. Radioactivity levels in tissues of chickens were less than 2% 
of the total dose of radioactivity administered as tritiated (3H) 
monensin (3). Ninety-eight percent of· remaining radioactivity was 
recovered from feces and urine. Most of the radioactivity of the 
tissues was associated with the water of the tissue indicating metabolic 
breakdown of tritiated monensin. Tissue levels of radioactivity dropped 
rapidly after withdrawal of medication. 
Radioactive monensin c14c) was administered orally to steers and 
fecal and urinary radioactivity was monitored daily (30). At least 75% 
of the dose was excreted in the feces within three days. All 
radioactivity excreted was in the feces; none was detected in urine. 
The following tissues were collected from steers fed radioactive 
monensin and were analyzed for carbon-14: liver, muscle, fat, kidney, 
heart, lung, spleen and blood. Liver was the only tissue that contained 
radioactivity levels greater than those of untreated controls. The 
14 
quantity of radioactivity in liver was the equivalent of 0 .59 ppm 
monensin. The liver was then assayed and found to contain 5-15 ppb 
monensin. This indicated that 97+% of the radioactivity in the liver 
was incorporated within metabolites of monensin. 
In a comparative study of the metabolism of monensin in monogastric 
animals (rats) versus ruminants (steers), rats metabolized more than 95% 
of orally administered c14c) monensin whereas steers metabolized 
50-60% of the monensin (29). The difference was assumed to be due to 
differences in absorption of monensin. A large number of metabolites 
were produced by both species. Absorbed monensin was excreted entirely 
in bile. Bile from a steer fed [ 14c] monensin contained radioactivity 
equivalent to 14 ppm monensin. By fractionation of the bile, 97% of the 
radioactivity was found to be associated with monensin metabolites while 
only 3% consisted of unaltered monensin. 
Chemical Properties of Monensin 
Monensin was the first polyether antibiotic whose molecular 
structure was determined (31). The molecular formula of monensin is 
c36H62o11 (molecular weight 670) (32). The sodium salt has a molecular 
formula of c36H61011 Na and a molecular weight of 692. 4 (32). It is 
further characterized by the absence of ultraviolet absorption. 
Monensin is somewhat unique because the acid and salt forms are readily 
extracted from water by organic solvents (26). Monensin and its sodium 
salts are slightly soluble in water (0.1 mg/ml), and are more soluble in 
hydrocarbons. Monensin is stable in alkalis and unstable in acids. 
Donoho et al. (29) investigated the extent of degradation of monensin in 
the alimentary canal of ruminants by incubating monensin for 2 days in 
15 
cattle feces (37°c); for 5 hours in ovine abomasal fluid (38°); and 
0 
overnight in ruminal fluids from steers (38 C) ; at least 90% of the 
monensin was recovered in all cases. Thus, monensin was not extensively 
degraded in the alimentary canal of ruminants. 
The pKa of monensin is 6.65 in 66% N,N-dimethylformamide. 
Transformations involving the hydroxyl groups bring about considerable 
change in the pKa as exemplified by the acetylation of primary and 
secondary hydroxyl groups resulting in a pKa of 7.6. 
Monensin is extracted with methanol from the fermentation broth of 
cultures of Streptomyces cinnamonen~is. It is obtained as a mixture of 
at least four related molecular species differing only by a few CH2 
groups (16). Monensin (Monensin A) is predominant. Stark, Nox and 
Westland (33) were able to increase monensin yields from 150 mg/ml of 
broth to 5000 mg/ml by selecting certain optimum strains of the fungus, 
increasing aeration of the broth, optimizing temperature of the culture, 
adding selected minerals to the medium and by supplementing the medium 
with certain oils. 
The monensin molecule is a carbon chain with a terminal carboxylic 
group. Five oxygen atoms form five and six membered rings in the carbon 
chain. Branching off the carbon chain are seven methyl-, one ethyl-, 
three alcohol-, and one methoxy- groups. 
Monensin complexes with the following cations in order of 
decreasing affinity: Na, K, Rb, Li, Cs. The rate of complexation to 
sodium compared to potassium is about 10:1, Na:K. The radius of 
monensin's hydrophilic cavity allows it to complex with monovalent 
0 
cations whose diameter is within the range of 1.0 to l.45A and slightly 
-
beyond (16). 
CHAPTER III 
MATERIALS AND METHODS 
Six healthy horses of different breed and of different sexes, 3 
males and 3 females, 2 to 10 years of age were used in this study. The 
horses were wormed with 2 gm/ 100 pounds body weight thiabendazole one 
week before monensin dosage and allowed to acclimatize in new quarters 
for 30 days. R 1 The horses were fed Omalene mixed grain diet (0. 75 
lb/100 lb of body weight) and prairie hay free choice. Blood was drawn 
from the jugular vein for complete blood counts (CBC) and serum 
chemistry tests 24 hours before monensin administration. 
Complete physical examinations and electrocardiograms (ECG) were 
done 24 hours before dosing. Horses 1, 2, and 3 were given single doses 
of monensin. Monensin was administered via stomach tube in a premix (60 
grams monensin/pound of premix) mixed with water to make a slurry. The 
horses were dosed according to the following schedule. 
Horse 111 25 mg monensin/kg body weight 
Horse 112 5 mg monensin/kg body weight 
Horse 113 2 mg monensin/kg body weight 
Horse #4 was given monensin in the feed (318 mg of premix contain-
ing 60 gm monensin/pound of premix) twice daily for 30 days. The 
1 Ralston Purina Company: Checkerboard Square, Saint Louis, Missouri 
63188. 
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monensin containing premix was mixed by hand into 3.5 pounds of grain 
ration at each feeding. This diet provides a daily dosage of monensin 
of approximately 0. 3 mg/kg. Prairie hay was available free choice. 
Horses #5 and 6 were used as controls for histologic and ultrastructural 
studies. 
Horses 1, 2, and 3 were observed constantly after dosing. The 
following observations were recorded hourly: Packed cell volume (PCV), 
total protein, pulse rate, rectal temperature, respiratory rate, mucous 
membrane coloration, mucous membrane capillary refill time, and presence 
or absence of borborygmus. Clinical signs were recorded as they 
occurred. Electrocardiograms were recorded shortly after clinical signs 
commenced and at an advanced stage of the poisoning episode. Blood 
collected from the jugular veins in EDTA and plain tubes was submitted 
for complete blood count (CBC) and serum emzyme chemistry tests every 
four to six hours after clinical signs became evident. The following 
serum enzyme chemistry tests were performed: total bilirubin, direct 
bilirubin, blood urea nitrogen (BUN), calcium, chloride, creatine 
phosphokinase (CPK), glucose, lactic dehydrogenase (LDH), magnesium, 
phosphorus, potassium, protein, serum aspartate aminotransferase (AST) , 
sodium and triglyceride. 
Complete necropsies were performed immediately after each horse 
expired. R 2 Horses 4, 5, and 6 were euthanatized with Sleepaway I.V. 
Brain and spinal cords were fixed in 30% formalin. Other tissues were 
fixed in 10% formalin. 
2 R Sleepaway Fort Dodge Laboratories, Fort Dodge, Iowa, 10501 
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Tissues collected for electron microscopy were excised, sectioned 
and immersed in fixative within 5 to 10 minutes after death. 
Myocardium, diaphragm, liver and kidney were cut in 1 mm squares and 
immersed in an adequate volume of buffered glutaraldehyde (10 mg 8% 
glutaraldehyde, 30 ml .27 M cacodylate buffer, .5 ml acrolein, .02 gm 
CaC12 , lOml distilled water, pH adjusted to 7.4 with 1 N HCl, osmolarity 
= 500) for 2 hours. The tissues were then washed twice in buffer, 
washed twice in water, postfixed in 2% Oso4 for l~ to 2 hours, washed 
thoroughly in water (four washes for 1 hour), stained in 1% aqueous 
0 
uranyl acetate overnight at 60 C, dehydrated and embedded in epoxy with 
the following schedule: 
1. 50% ETOH 15 minutes 
2. 70% ETOH 15 minutes 
3. 90% ETOH 15 minutes 
4. 95% ETOH 15 minutes 
5. 100% ETOH 15 minutes 
6. 100% ETOH 15 minutes 
7. 100% ETOH 15 minutes 
8. Propylene oxide 15 minutes 
9. Propylene oxide 15 minutes 
10. Propylene oxide 15 minutes 
11. 1: 1 propylene oxide and EPON 4 hours 
12. 1:1 propylene oxide and EPON overnight 
13. Embed in 100% EPON -- place 0 in vacuum oven at 60 C for 
approximately 48 hours. 
Thick sections were examined by light microscopy. Areas of the 
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blocks were selected for thin sectioning. Viewing was done with a 
3 Philips 200 transmission electron microscope • 
Tissues fixed in buffered formalin for examination by light 
microscopy were blocked preparatory to processing and embedment, washed 
in six baths of absolute Cellusolve 4 , three baths of toluene and 3 
baths of paraffin. Tissue washing was done in a Lipshaw Trimatic5 , 
automatic tissue processor. Tissues were then embedded in paraffin, 
sectioned with a microtome and stained with Hematoxylin and Eosin with a 
Ames Histotech Automatic Slide Stainer6 • The following tissues were 
examined by light microscopy: cerebrum, cerebellum, spinal cord, 
pituitary, thyroid, esophagus, thymus, pre scapular lymph node, lung, 
heart, mediastinal lymph node, diaphragm, stomach, duodenum, jejunum, 
ileum, cecum, dorsal colon, adrenal gland, kidney, urinary bladder, 
spleen, pancreas, liver, and choroid plexus. 
The following samples were collected for monensin analysis: urine 
(when available), kidney, liver, stomach content, small intestine 
content, cecal content and feces. Samples were analyzed for monensin by 
the thin layer chromatography and spectrophotometry method as described 
by Golab (9). 
3Philip' s Electrical Instruments Inc. , 85 McKee Dr. , Mahwah, NJ 
07430. 
4cellsolve, McKesson Chemical Co. Crocker Plaza, One Post Street, 
San Franscisco, California, 94104. 
51ipshaw Trimatic, Lipshaw Manufacturing Corporation, Detroit, 
Michigan, 48210. 
6Ames Histotech, Miles Laboratories, Elkhart, Kansas. 
CHAPTER IV 
RESULTS 
Clinical Signs 
Horses #1, 2, and 3 received single oral doses of monensin at · 25, 5 
and 2 mg/kg respectively. Onset of clinical signs occurred at 4 to 6 
hours and did not appear to be dose related at the levels administered. 
Figure 1. Horse #2 (5 mg/kg monensin per os) with 
patchy sweating. 
Refusal of grain was the earliest sign observed, however, horses 
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continued to eat prairie hay until 4-8 hours before death. Intermittent 
patchy sweating began 5-9 hours after treatment, occured first in the 
axillary, inguinal and tail head regions and rapidly became more profuse 
and generalized (see Figure 1). 
Intermittent ataxia began 5 hours after dosing in horses given 25 
and 2 mg/kg, however the horse given 5 mg/kg did not have ataxia until 
17 hours post-treatment. Early ataxia was characterized by swaying of 
the hindquarters and overextension of the hind limbs when walking. 
Periods of normal gait intervened between periods of locomotor 
difficulty. Affected horses fell against the side of the pen and then 
regained their balance. 
recumbent. 
Ataxia progressed until the horses became 
While in lateral recumbency, horses would periodically sweat 
profusely and would look at their sides as if suffering mild abdominal 
pain. No kicking at the abdomen or attempts at rolling were observed. 
The horses then unsuccessfully attempted to rise and pawed with their 
front feet while in lateral recumbency. Horses died approximately 3 
hours after becoming terminally recumbent. 
Heart rates doubled to 80-90 per minute four to six hours after 
dosing and remained elevated until death. Respiratory rates remained 
normal until a few hours before death when the respiratory rate tripled 
(80 respirations/min.) Intestinal motility was variable throughout the 
poisoning episode with borborygmus being present in about half of the 
hourly examinations. 
Capillary refill time remained normal until shortly before death 
when mucous membranes of the mouth became muddy and capillary refill 
time increased. 
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The horse that received 25 mg/kg died 31 hours after receiving 
monensin, the other horses that received single oral doses died 33 hours 
after dosing. 
The following clinical signs were noted in horse #4 that received 
monensin in the feed at 30 ppm for 30 days. The heart rate, respiratory 
rate, temperature, color of mucous membranes, capillary refill time, and 
intestinal motility remained normal throughout the 30 day feeding 
period. Although appetite was only slightly depressed throughout the 
trial, horse #4 lost 54 pounds. On days 19 and 29, the horse became 
ataxic and fell against the side of the pen. Ataxia, primarily in the 
hindquarters, continued for about 15 minutes. Patchy sweating occurred 
with each bout of ataxia. 
Clinicopathologic Observations - Single Oral Dose 
The packed cell volume of all horses that recieved a single oral 
dose of monensin increased moderately about ten hours after dosing and 
remained elevated until death (Table I). 
The white blood cell count (WBC) reflected a stress response with a 
mild to moderate leukocytosis due to neutrophilia, lymphocytopenia and 
eosi~openia. The total white blood cell count (WBC) increased by 29 to 
43% nine hours after dosing and remained elevated until death (Table I). 
Total bilrubin increased to above normal limits (normal 0.0 - 2.7 
mg/100 ml) about 24 hours after dosing and reached a high of 3.3 mg/100 
ml, 4.4 mg/100 ml and 2.9 mg/100 ml in horses #1, 2 and 3 respectively. 
Direct bilirubin increased only slightly and remained within normal 
limits (O.O - 0.4 mg/100 ml) throughout the toxic episode. 
TABLE I 
BLOOD PARAMETERS OF HORSES GIVEN A SINGLE ORAL DOSE OF MONENSIN 
Parameter Time (hrs) 
0 9 24 29 
- -
Horse Ill: Total WBCa 3 (Cells/mm ) 9200 11900 11400 9300 
(25 mg/kg) Neutrophils 3 (Cells/mm ) 5244 8568 10374 8184 
Lymphocytes 3 (Cells/mm ) 3312 2975 570 897 
PCV (%)b 36 36 54 46 
Horse 112: Total WBCa 3 (Cells/mm ) 14900 21300 18200 17300 
(5 mg/kg) Neutrophils 3 (Cells/mm ) 6407 16827 15834 14532 
Lymphocytes 3 (Cells/mm ) 6854 3195 1638 2076 
PCV (%)b 3 (Cells/mm ) 34 50 40 41 
Horse /13 Total WBCa 3 (Cells/mm ) 9600 13900 14600 14200 
(2 mg/kg) Neutrophils 3 (Cells/mm ) 5856 11954 12410 12780 
Lymphocytes 3 (Cells/mm ) 3552 1807 2190 1278 
PCV (%)b 3 (Cells/mm ) 36 38 38 42 
a White Blood Cell Count 
b Packed Cell Volume 
N 
w 
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Blood urea nitrogen (BUN) increased only slightly reaching above 
normal levels (normal 10-20 mg/100 ml) in one horse (5 mg/kg monensin 
per os) with a high of 36 mg/100 ml at 28 hours post dosage. 
Serum calcium levels remained unchanged in the horse given 25 mg/kg 
monensin per os. Horse tt2 (5 mg/kg monensin per os) had a slight 
decrease in serum calcium with a low of 8 mg/100 ml eight hours after 
dosing (normal 11.2 - 13.6 mg/100 ml). Horse #3 (2 mg/kg monensin per 
os) had a decrease in serum calcium from 10.3 mg/100 ml to 9.3 mg/100 
ml which then returned to 10.4 mg/100 ml late in the toxic episode. 
Serum chloride concentrations decreased to slightly below normal 
(normal 99-109 mg/100 ml) in all horses given single oral doses of 
monensin with a low of 88 mg/100 ml in horse #3 ( 25 mg/kg monensin per 
os) seven hours after dosing. Generally, serum chloride concentrations 
were maintained in the 90 to 100 mg/100 ml range throughout the 
experiment. 
Serum creatine phosphokinase (CPK) concentrations increased to 
200-400 IU/L (normal 2.4 - 23.4 IU/L) in all horses about eight hours 
after administration of monensin and remained elevated until death. 
Serum glucose concentrations increased to 150 - 300 mg/100 ml 
(normal 60 - 110 - mg/100 ml) in all horses six hours after dosing and 
remained in this elevated range until death. 
Serum lactic dehydrogenase (LDH) concentrations increased slightly 
to 250 - 500 IU/L (normal 41-104 IU/L) six hours after dosing and 
remained high until death. The horse that recieved 25 mg/kg monensin 
per os had a high serum LDH concentration of 1600 IU/L twenty-four hours 
after dosing. 
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Serum inorganic phosphorous concentrations were variable with horse 
#3 (2 mg/kg monensin per os) having a gradual decrease in serum inor-
ganic phosphorous to 1.7 mg/100 ml (normal 3.1 - 5.6 mg/100 ml) while 
horse 112 (5 mg/kg monensin per os) had a gradual increase in serum 
phosphorous concentrations from 3.8 mg/100 ml to 5.1 mg/100 ml. Serum 
inorganic phosphorous concentrations remained within normal limits for 
horses #1 and #2. 
Serum potassium concentrations remained within normal limits (2.4 -
4.7 meq/l) for all horses recieving single oral doses of monensin. 
Serum total protein concentrations gradually increased throughout 
the toxic episode but only exceeded normal limits (5.7 - 7.9 mg/100 ml) 
in one horse (25 mg/kg monensin per os) when it reached a serum concen-
tration of 8.6 mg/100 ml approximately eighteen hours after dosing. 
Serum aspartate aminotransferase (formerly glutamic-oxalacetic 
transaminase SGOT) concentrations increased slightly above normal 
(normal 58.0 - 94.0 IU/L) levels and remained in the 100 - 200 IU/L 
range. 
Serum sodum concentrations generally remained within normal for all 
horses throughout the experiment. 
Clinicopathologic Observations 
Thirty Day Feeding 
Complete blood counts and serum chemistries were analyzed at three 
day intervals throughout the thirty-day feeding trial. 
The packed cell volume varied from 28% to 37% throughout the 
experiment. The white blood cell count ranged from 10 ,500 WBCs to 
3 16,000 WBCs/mm • Total bilirubin and blood urea nitrogen remained 
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within normal limits. Serum calcium ranged from.low normal (normal 11.2 
- 13.6 mEq/L) to slightly below normal with a low of 9.7 mEq/L on day 
26. Serum chloride ranged f ram low normal (normal 99-109 mEq/L) to 
below normal with a low of 93 mEq on day 3. Serum CPK ranged from 33 
IU/L to 120 IU/L (normal 2. 4 - 23. 4 IU/L) with the highest value 
recorded on day 1 taken before the experimental feed was introduced. 
Serum glucose concentrations generally remained within normal lmits. 
Serum LDH concentrations ranged from 270 IU/L on day 1 (before 
treatment) to 90 IU/L on day 6 but were generally above normal limits 
(normal 41 - 104 IU/L). Serum inorganic phosphorous, potassium and 
protein remained normal throughout the experiment. Serum aspartate 
aminotransferase (AST) concentrations ranged from normal (58 - 94 IU/L) 
to a high of 160 IU/L) on day 24. The pretreatment AST concentration 
was also elevated (160 IU/L). 
Electrocardiographic Observations 
Electrocardiograms were taken prior to monensin administration and 
again during clinical episodes. 
Horses given single oral doses of monensin had prolonged atrial and 
ventricular depolarization and repolarization when compaired to predose 
electrocardiograms. The prolonged intervals were, however, within 
normal limits. Increased S wave amplitude was also noted. 
Horse 113 (2 mg/kg monensin per os) had an abscence of P and 
increased T waves after monensin administration. 
Horse #4 (30 day feeding trial) had prolonged atrial and 
ventricular depolarization with slightly prolongated repolarization. 
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Necropsy 
Horses number 1 , 2, and 3 died thirty-one to thirty-three hours 
after dosing. Lesions in the myocardium were similar in all three 
horses on gross necropsy examination. There was a diffuse pale 
streaking throughout the ventricular myocardium and the myocardium tore 
easily. The myocardium had increased firability. Other changes 
observed on gross necropsy examination, not consistently seen in all 
three horses,- included: accentuated hepatic lobular pattern (horse 1), 
pulmonary congestion and edema with froth in the air passages (horse 2), 
shrunken, firm spleen (horse 1, 2) and ecchymotic hemorrhage in the left 
caudal lung lobe (horse 3). No changes were noted in horse number 4 
(given 30 ppm monensin in the feed for 30 days) on gross necropsy 
examination. 
Histopathology 
Histopathologic changes were noted in the heart and liver of all 
horses given monensin. Changes seen consistently in the myocardia of 
horses given monensin were: swollen and shrunken myocardial fibers with 
dense acidophilic cytoplasm, loss of longitudinal and cross striations, 
granulation of the sarcoplasm of affected cells, foci of myocytic 
necrosis, and intracytoplasmic vacuolization with minimal-to-moderate 
inflammatory reaction. These changes were evenly scattered and involved 
approximately 5% of myocytes. In addition to the above described 
changes, horse #3 (2 mg/kg) had neutrophilic foci associated with 
myonecrosis (Figure 2). Although horse 4 was given low doses of 
monensin in the feed for thirty days, the changes noted in the myo-
cardium on histopathologic examination are characteristic of an acute 
28 
degenerative process. These changes probably occurred during the bout 
of ataxia and sweating on day 29. 
Changes noted on microscopic examination in the liver of horses 1, 
2, and 3 were similar and consisted of central and midzonal vacuoli-
zation of hepatocytes (fatty change). Hepatopathy in horse 4 (given 30 
ppm monensin in the feed for 30 days) consisted of hepatocytic swelling 
and vacuolization with irregular granulation and reticulation of 
hepatocytic cytoplasm. There was mild bile duct proliferation. 
Swollen and shrunken myocytes with increased eosinophilic staining 
and loss of cross striations were present in diaphragmatic muscles of 
horses 1, 2 and 3. These changes were less frequent and less severe 
than those noted in the myocardium. 
Other histopathologic findings noted in some but not all experi-
mental horses include: necrotic cellular debris in germinal centers of 
lymph nodes and in splenic Malpighian corpuscles (horses 2 and 3), focal 
pulmonary alveolar and septal edema (horses 2 and 3), and mild changes 
in the kidneys (horses 1 and 2) consisting of occassional dilated 
collecting tubules containing pink proteinaceous material and a few 
erythrocytes, congestion of glomerular capillaries and vacuolization of 
proximal tubular epithelial cells. In addition, horse 2 had nephrosis 
of approximately five percent of the distal tubules. Horses number 3 
and 4 had numerous eosinophils in the submusosa of the cecum and colon. 
Ultrastructural Changes 
Ultrastructural changes were noted in the myocardium of all 
experimental horses. Lesions were not observed in the tissues of 
control horses. In experimental horses cardiac mitochondria were 
Figure 2. Light micrograph of left ventricle myo-
cardium from experimental horse #3 (2 mg/kg mon-
ensin per os) with degenerative myocytes (M), 
densly acidophilic cytoplasm, myonecrosis and 
inflammatory cell infiltrate. 
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frequently enlarged 2 to 5 times normal size (Figure 4) • Cristae of 
enlarged mitochondria were often fragmented. There was decrease in the 
electron density of the matrix of mitochondria. Vesicles were 
frequently found between cristae and in some cases lipids internally 
replaced degenerated cristae and ground substance (Figure 5). 
Fragmentation of my of ibrils was noted in the myocardia of experimental 
horses with occasional associated disruption of myofibrillar 
organization (Figure 5). 
Hepatocytes of experimental horses had mitochondria that were 
occasionally moderately to markedly enlarged (2 to 4 times normal size) 
with decreased matrix density and fragmentation of cristae. There was a 
slight to moderate increase in the number of peroxisomes in experimental 
horse hepatocyes (Figures 8,9). Changes in the mitochondria of 
hepatocytes were most evident in the horse that received monensin daily 
for 30 days. Lipid droplets were present in the hepatic cytoplasm of 
horse #2 (5 mg/kg monensin). 
Significant ultrastructural changes were not noted in the kidney 
and diaphragm of experimental horses. 
Figure 3. Electron micrograph of a cardiac myocyte from a 
control horse with mitochondria (M) and myofibrils (f) 
being evident. 
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Figure 4. Electron micrograph of a cardiac myocyte from 
experimental horse #3 (2 mg/kg per os) with mitochondria 
with enlarged cristae and loss of matrix, lipid vesicles 
(1), and lipid replacement of mitrochondrial matrix (lm), 
and fragmentation of myofibrils (f). 
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Figure 5. Electron micrograph of a cardiac myocyte from 
experimental horse #3 (2 mg/kg per os) showing disruption 
of myofibril organization in addition to the changes 
noted in figure 2. Mitochondria (m), myofibril (f), 
lipid vesicle (1). 
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Figure 6. Electron micrograph of a hepatocyte from an 
untreated horse used as a control. Nucleus (N) 
mitochondria (m), smooth endoplasmic reticulum 
rough endoplasmic reticulum (rer). 
• (ser), 
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Figure 7. Electron micrograph of a hepatocyte from an untreated horse 
used as a control. Nucleus (N), mitochondria (m), smooth endoplasmic 
reticulum (ser), rough endoplasmic reticulum (rer), bile caniliculus 
(b). 
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Figure 8. Electron micrograph of a hepatocyte from horse 
#3 (2 mg/kg monensin per os) with decreased electron 
density of mitochondria matricies (m) and indistinct 
cristae, and peroxisomes (p). 
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Figure 9. Electron micrograph of a hepatocyte from horse 
#4 given monensin in the feed at 30 ppm for 30 days. 
Note enlarged mitochondria (m) with indistinct cristae, 
and peroxisomes (p). N (nucleus), smooth endoplasmic 
reticulum (ser), rough endoplasmic reticulum (rer}, 
biliary caniliculus (b). 
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Figure 10. Electron micrograph of same hepatocyte as 
Figure 9 with greater mignification showing bilaminar 
membrane (arrows) of mitochondria (m), fragmentation of 
cristae (arrow heads), rough endoplasmic reticulum 
(rer), nucleus (N). 
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Toxicology 
The following tissues and samples were analyzed for monensin with 
the following results: 
In horse #1 (25 mg/kg) no monensin was detected in urine, kidney, 
liver or in contents of small intestine. Contents of the stomach 
contained 0. 8 ppm monensin and contents of cecum contained 1. 7 ppm 
monensin. 
Monensin was not detected in contents of the stomach and cecum from 
horse'#2 (5 mg/kg). 
Monensin was not detected in contents of cecum from horses 113 (2 
mg/kg) and #4 (30 ppm in feed for 30 days). 
CHAPTER V 
DISCUSSION 
Monensin is an ionophoric antibiotic that is effective as a feed 
additive in cattle and as a coccidiostat in poultry. Monensin is highly 
toxic to most mammals and is especially toxic to horses (S3) (S4) (SS) 
.(56) (57) (58) (59). As an ionophore it has the ability to penetrate 
biologic membranes and to alter ion concentrations thus adversely affect 
intercellular and intracellular ionic gradients (60) (61) (62) (63) (64) 
(65). 
The clinical signs observed in three horses given single oral doses 
of monensin were similar to those previously described in the 
literature (1) (34) (35) (37) (38). 
The horse that received monensin in the feed at 30 ppm for 30 days, 
had signs similar to those of acute monensin toxicosis on two occasions. 
This is the first report of clinical signs, other than partial anorexia, 
associated with this low dose (0.3 mg/kg per os daily). 
An oral LD50 of 2-3 mg/kg was estimated for monensin in horses from 
early studies at Eli Lilly Research Laboratories (39). This study was 
based on ten horses given various levels of monensin in the feed ranging 
from 33 ppm to 331 ppm. Because of the cost of horses, statistically 
significant numbers of animals were not tested in order to precisely 
determine the oral Ln50 of monensin. It should be noted from this study 
that at least some horses have significant clinical signs and morpho-
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logic changes when fed approximately the same concentration of monensin 
that is recommended for cattle (33 ppm). 
Clinicopathologic changes were nonspecific and generally mild-to-
moderate. Horses that received single oral doses of monensin had 
leukograms that were indicative of stress of mild intensity. 
Only one horse had a mild increase in blood urea nitrogen (BUN) 
above normal values. Matsuoka (34) considered a BUN of 21.5 mg/100 ml 
significant and correlated this concentration of BUN with the toxic 
tubular nephritis that was observed by histopathologic examinations of 
tissues from horses dosed with monensin. Amend et al. (40) noted that 
BUN concentrations may be elevated to twice normal in severely affected 
animals. Based on our study and those noted above, it is the authors 
opinion that horses suffering from monensin toxicosis will have a 
normal-to-slightly elevated BUN. 
Serum calcium concentrations decreased mildly in two of the three 
horses given single oral doses of monensin. This was in agreement with 
the findings of Amend (40) who noted that serum calcium levels initially 
decline by 1 - 2 mg/dl following monensin ingestion. 
Serum creatine phosphokinase (CPK) concentrations increased 
significantly in all horses given single oral doses of monensin. In 
studies of CPK isoenzymes by Amend et al. (40), CPK isoenzyme elevations 
were determined to be the result of skeletal muscular involvement with 
little contribution of cardiac or brain isoenzymes. Their findings were 
somewhat surprising because the lesions in the heart in the present 
study were more severe and the heart is believed to be the primary 
target organ of monensin toxicosis in the horse. Myopathy of skeletal 
musculature was present in the study at hand-, however, the lesions were 
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microscopically less severe than those observed in the hearts of 
affected 
horses. 
Serum lactic dehydrogenase (LDH) concentrations also increased 
significantly in horses that received single oral doses of monensin. 
Isoenzyme studies of LDH by Amend et al. (40) had substantial increases 
in those fractions associated with cardiac muscle and erythrocytes with 
little disturbance of the LDH-isoenzymes arising from the liver or 
skeletal muscle. 
Serum potassium concentrations remained within normal limits in our 
study in contrast to that of Amend et al.(40) who described a transient 
hypokalemia with serum potassium declining by 1 - 2 mEq/liter in the 
first 24 hours after dosing. 
A gradual increase in serum total protein was observed throughout 
the toxic episode and this correlated well with the mild-to-moderate 
increase in packed cell volume (PCV) (see table I). This was believed to 
be due to hemoconcentration. Amend et al.(40) stated that ponies 
poisoned with monensin suffered a peracute crisis of hypovolemic shock 
that was secondary to toxic nephrosis. In the study at hand, changes in 
BUN, PCV, serum total protein concentration and microscopic evaluation 
of the kidneys suggest mild to moderate hemodynamic changes and mild 
degenerative changes in the kidneys with occasional nephrosis. It is 
doubtful that the renal changes indicate nephrosis of significant 
proportions. 
Serum aspartate aminotransaminase (AST) increased mildly. Because 
this enzyme is located in the mitochondria and cytoplasm of cardiac and 
skeletal myocytes as well as in hepatocytes, one might expect a more 
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. dramatic increase in AST as was noted in studies by Amend et al. (40). 
It should be noted that Amend et al.(40) used ponies rather than horses 
as were used in this study and the dosages used by Amend et al.(40) were 
not stated in the literature. 
In the present study, electrocardiographic changes due to 
intoxication of horses by monensin were interpreted by veterinary 
cardiologist Gerard Rubin (41) as being due to right heart strain or 
electrolyte abnormality. Amend ( 40) and Whitlock (1) described "S-T" 
segment depression as being indicative of myocardial injury. Francene 
Mallone (42) and Amend (40) noted "T"-wave depression suggestive of 
hypokalemia. "T"-wave depression was not noted in our study but an 
increased amplitude of the "T"-wave was observed in horse lt3 (2 mg/kg 
monensin/os). This was suggestive of hyperkalemia. This apparent 
conflict in results might be explained by the results of studies by 
Smith et al. (43) wherein small doses of monensin resulted in increased 
intracellular potassium concentrations in 3T3 fibroblast cell cultures 
while higher doses of monensin caused a net loss of potassium from the 
cells. 
Most of the dramatic and easily observed changes at gross necropsy 
examination were nonspecific and suggestive of agonal death. Changes 
noted in the heart of horses that received single oral doses of monensin 
were subtle and diffuse but were nevertheless suggestive of significant 
myocardial degeneration. The myocardium of affected horses had a 
diffuse pale streaking throughout, was excessively friable, and could be 
easily torn. The changes in color were similar to those that develop 
soon after death in otherwise normal animals as a result of postmortem 
autolysis. 
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The most remarkable change noted on histopathologic examination of 
tissues from affected horses was diffuse myocardial degeneration. The 
degeneration was easily detected because of the presence of shrunken 
myocytes with dense acidophilic cytoplasm, 
cross striations, loss of Cohnheim's 
loss of longitudinal and 
fields, granulation and 
vacuolization of 
reaction. These 
sarcoplasm with minimal-to-moderate inflammatory 
diffuse cardiac changes were considered to be 
nonspecific because they can be observed in other conditions such as 
cobalt induced cardiomyopathy (45), isoproterenol-induced myocardial 
necrosis and Cassia occidentalis toxicosis. ( 46). Cardiomyopathy was 
not noted in initial studies by Matsuoka (39) who considered toxic 
hepatitis and toxic tubular nephritis to be the primary morphologic 
changes resulting from monensin poisoning in horses. In subsequent 
studies by others myocardial degeneration has been observed (37) (40) 
(1). 
Changes noted in the livers of horses given single oral doses of 
monensin were mild and nonspecific vacuolization of hepatocytes. 
Changes noted in the horse given monensin in the diet for 30 days were 
also mild and consisted of mild granulation of hepatocyte cytoplasm with 
mild hyperplasia of bile ducts. These changes in the liver were in 
contrast to the findings of others who have reported severe liver 
degeneration and necrosis in horses suffering from monensin poisoning 
(34) (37). However, Amend et al. (40) concluded that the toxic effects 
of monensin in the liver were minimal. 
Only mild changes were noted microscopically in the kidneys of the 
two horses that were given the largest doses of monensin. Matsuoka (39) 
and Amend et al. (40) implied that renal impairment was of major 
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importance in monensin poisoning of horses and ponies respectively. It 
is my opinion that renal changes are mild and are only a contributory 
factor in monensin poisoning in horses. 
Significant ultrastructural changes were noted in the myocardia of 
all experimental horses and consisted of enlargement of mitochondria 
with fragmentation of cristae, and fragmentation and disruption of 
myofibrillar organization. In studies of ultrastructural changes in 
ponies poisoned with monensin, Mollenhauer et al. (36) noted similar 
changes in mitochondria but found no change in myofibrils. Mitochondria 
are among the most sensitive of cellular organelles and frequently have 
the changes noted above when cells undergo degenerative processes. 
Myofibrillar degeneration is also a nonspecific change characteristic of 
diffuse myocardial degeneration. Initial changes at the centers of 
experimentally induced ischemic infarcts were mitochondrial swelling and 
dilatation of tubules of the sarcoplasmic reticulum with no change in 
myofibrils (44). Changes in the ultrastructure of the myocardium that 
were similar to those found in this study have been reported from a 
variety of cardiotoxins including cobalt poisoning (45), thiamine 
deficiency, alcoholism, and Cassia occidentalis toxicosis (46)' 
reserpine, digitalis, and poisoning resulting from the antimalarial drug 
plasmocid (47). 
It is interesting to note that degenerative changes were seen at 
the ultrastructural level in all cardiac myocytes examined from treated 
horses while light microscopic changes were noted in only approximately 
5% of myocytes. Cardiac myocytes examined by electron microscopy were 
not selected on the basis of having degenerative changes at the light 
microscopic level. This suggests that many, if not most, cardiac 
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myocytes were undergoing ultrastructurally visible degenerative changes 
at the time of death. 
Ultrastructural changes were observed in the livers of all 
experimental horses. Abnormalities were not observed in livers of 
control animals. The most consistent changes were enlargement of 
mitochondria with decreased matrix density and cristae distortion. An 
increase in peroxisomes was also observed. Mollenhauer et al. (36) 
found that the most obvious changes in hepatocytes of ponies poisoned 
with monensin were increased smooth endoplasmic reticulum and decreased 
rough endoplasmic reticulum. Increased numbers of peroxisomes were also 
observed by Mollenhauer et al. (36). Peroxisomes are small membrane-
bound dense bodies that originate from the endoplasmic reticulum and 
contain catalase and urate oxidase enzymes. It has been proposed that 
peroxisom.al enzymes oxidize hydrogen peroxide formed during cellular 
injury and thus protect the cell from further injury (47). The exact 
function of peroxisomal enzymes is unknown although they have been 
associated with metabolism of lipids, cholesterol and steroids, and 
gluconeogenesis. Most changes noted in hepatocytes of affected horses 
involved distortion of membranes of mitochondria with infrequent rupture 
of membranes. Membrane distortion without rupture was interpreted as a 
reversible change. 
Residues of monensin were found only in stomach contents and in 
cecal content of horse Ill (25 mg/kg monensin/ os). The analysis was 
performed by the official AOAC method of Golab (9). This method is 
colorimetric and is qualitative for monensin in feeds. Although this 
method has been shown to identify as little as 1 ug. of monensin, it has 
not been validated for levels of monensin below 90 grams per ton. The 
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most precise method of quantitation of monensin requires microbiologic 
plate or turbidimetric assays (48) (10) (8) (49) (50) (51) (52). 
Tissue analysis and analys_is of gastrointestinal contents from horses 
with suspected monensin poisoning would be of value although there is a 
high potential for false negatives. The presence of any monensin in 
such samples would indicate exposure and would strongly support a 
diagnosis of monensin toxicosis that was based only on history, feed 
analysis, and histopathologic evaluation. 
Studies of metabolites of monensin in rats and steers suggest that 
monensin is well absorbed in rats (95% metabolized) and steers (50-60% 
metabolized) (29) (30). Quantitatively, monensin and it's metabolites 
are found primarily in the feces. . Bile contains the next greatest 
concentration of monensin followed by liver. Ninety-seven percent of 
the monensin detectable in the liver and bile is in the form of 
metabolites of monensin. Neither radioactively labeled monensin nor its 
metabolites have been found in other tissues. It was believed that 
these findings suggest that monensin is well absorbed in mammals 
(especially monogastrics), and that most of the monensin that is 
absorbed is removed from the circulation by the liver ("first pass 
effect"). Monensin thus is absorbed, metabolized, and secreted into the 
intestine via the biliary system. Studies of metabolism wherein toxic 
doses of monensin were used have not been reported for any species. It 
is possible that toxic doses of monensin overload the ability of the 
liver to remove monensin from the splanchnic venous system thus allowing 
access to the heart and general circulation. The extreme sensitivity of 
the myocardium to monensin was demonstrated by studies of Saini et al. 
(24) who found maximum dilatation of coronary arteries in dogs after 
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intravenous injection of only 5 ug/kg monensin. Doses of 25 to 100 
ug/kg monensin by the intravenous route produced increased blood 
pressure, cardiac output and cardiac contractility. If the "first pass 
effect" is the protective mechanism that prevents ingested monensin from 
reaching the general circulation, it is interesting to speculate that 
inhaled monensin might gain access to the general circulation via the 
pulmonary circulation and have an adverse effect on the myocardium of 
persons who handle monensin daily such as employees of feed mill 
operators. It is also interesting to note that the Food and Drug 
Administration (FDA) has classified monensin as a class-I feed additive 
which requires only minimal handling precautions. 
The tissue distribution, rate and extent of metabolism and excre-
tion of radioactively labeled monensin in rats, steers, and chickens, 
suggests that, at pharmacologically active doses monensin does not 
accumulate to a significant degree in tissues. Thus, toxicosis as a 
result of "cumulative effect" from chronic ingestion of small amounts of 
monensin does not appear to be likely. It is likely, however, that 
repeated episodes of mild monensin poisoning could lead to scarring of 
the myocardium and eventual congestive heart failure. Single nonfatal 
episodes of monensin poisoning could also result in subsequent heart 
failure if the extent of myocardial damage was such that the remaining 
cardiac tissue could not compensate. 
Treatment for monensin toxicosis aimed at eliminating monensin from 
the gastrointestinal tract (gastric lavage, activated charcoal, mineral 
oil) and supportive cardiovascular therapy that includes fluids in 
moderation should be used. Horses that survive an acute episode of 
monensin toxicosis should be rested in a stall for 6 to 8 weeks to 
curtail cardiac activity. 
CHAPTER VI 
SUMMARY 
In this study horses were given varied toxic doses of monensin and 
were monitored noting clinical signs, clinical chemistry, hematology, 
electroc~rdiographic changes, gross necropsy, histopathology, ultra-
structural changes and toxicologic analyses. Clinicopathologic findings 
included: leukograms indicative of stress, mild decreases in serum 
calcium concentrations, increases in serum creatine phosphokinase 
concentrations, increases in lactic dehydrogenase concentrations, 
increases in serum total protein, packed cell volumes, and mild in-
creases in serum aspartate aminotransaminase concentrations. Electro-
cardiographic changes indicated right heart stress or electrolyte 
abnormality. On gross necropsy examination changes were seen only in 
the heart. Diffuse pale streaking throughout the myocardium was found 
and the myocardium was excessively friable. The principle organs that 
had light microscopic lesions were the hearts and livers. There was 
diffuse necrosis of the myocardia and hepatocytes were mildly 
vacuolated. Changes seen with electronmicroscopy in the hearts were 
enlargement of mitochondria with fragmentation of cristae, and 
disruption and fragmentation of myofibrils. Changes found in 
examination of the ultrastructure of hepatocytes were enlargement of 
mitochondria with distortion of cristae, and increased numbers of 
peroxisomes. Toxicologic analyses of various tissues and contents of 
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the gastrointestinal tracts were performed. Residues of monensin were 
found only in the gastrointestinal tract of one horse. 
The results of the study at hand were compared to those of similar 
studies found in the literature. Included were findings from the 
literature on studies of mechanisms of action of monensin in cells of 
mammals. From information derived from the results and information 
found in the literature I have speculated on the toxicodynamics of 
monensin poisoning in horses. I have tried to present the results of 
this study in proper perspective to provide the reader with an accurate 
anq thorough understanding of monensin poisoning in horses and to aid in 
making an accurate diagnosis of monensin poisoning in horses. 
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